Cytokinetics (NASDAQ:CYTK) Director B Lynne Parshall Sells 5,000 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) Director B Lynne Parshall sold 5,000 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the transaction, the director directly owned 10,784 shares in the company, valued at approximately $770,840.32. This represents a 31.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Price Performance

Shares of CYTK stock traded up $0.49 during trading on Tuesday, reaching $71.40. The company had a trading volume of 1,898,300 shares, compared to its average volume of 2,146,721. The firm’s 50 day simple moving average is $79.95 and its two-hundred day simple moving average is $72.33. Cytokinetics, Incorporated has a one year low of $44.91 and a one year high of $88.31. The company has a market capitalization of $8.88 billion, a PE ratio of -9.89 and a beta of 0.39.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.13. The company had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. During the same period in the previous year, the company earned ($1.12) EPS. The firm’s revenue for the quarter was down 57.1% compared to the same quarter last year. Analysts forecast that Cytokinetics, Incorporated will post -6 earnings per share for the current year.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reached a Phase 3 milestone in non-obstructive hypertrophic cardiomyopathy (HCM), highlighting progress for its cardiac-medicine pipeline and potentially expanding the company’s commercial opportunity. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM
• Positive Sentiment: New Phase 3 data provided an additional catalyst for CYTK, reinforcing investor focus on clinical execution and the potential value of its late-stage drug candidates. The company is also viewed by one analysis as approximately 34% undervalued, although such valuation estimates are subjective. Cytokinetics Presents New Phase 3 Data
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $140 price target, substantially above recent trading levels. The broader analyst consensus remains “Moderate Buy,” with a reported average target of $102.20. HC Wainwright Reaffirms Cytokinetics Buy Rating
• Neutral Sentiment: CEO Robert Blum sold 7,500 shares and EVP Andrew Callos sold 10,000 shares at an average price of $70.24. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing the signal that the sales reflect a new negative view of the business.
• Negative Sentiment: Wall Street Zen lowered its rating on Cytokinetics, creating a counterpoint to the predominantly bullish analyst coverage and potentially limiting near-term enthusiasm. Cytokinetics Stock Rating Lowered by Wall Street Zen

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CYTK. Barclays raised their target price on shares of Cytokinetics from $95.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Morgan Stanley raised shares of Cytokinetics from an “overweight” rating to a “buy” rating in a research report on Tuesday. Wells Fargo & Company upped their price target on shares of Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Stifel Nicolaus raised their price target on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research note on Friday, August 7th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and an average target price of $102.20.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its stake in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 673 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Cytokinetics during the 4th quarter valued at $27,000. Kestra Advisory Services LLC acquired a new position in Cytokinetics during the 4th quarter valued at $29,000. Quarry LP bought a new stake in Cytokinetics in the 3rd quarter valued at $30,000. Finally, Advisory Services Network LLC bought a new stake in Cytokinetics in the 3rd quarter valued at $32,000.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.